Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05196867 · ClinicalTrials.gov registry record · NA
Liver Cancer Prevention Randomized Control Trial
A NA study of Cirrhosis, Liver and Liver Diseases, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT05196867 is a NA study of Cirrhosis, Liver and Liver Diseases that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 49 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05196867, a NA study of Cirrhosis, Liver and Liver Diseases, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effectiveness of a behaviorally-based tailored disease management intervention in patients with fibrosis or steatosis and risk factors for cirrhosis.
Conditions Studied
Interventions
- BEHAVIORAL Intervention Group
- BEHAVIORAL Control Group
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2028-08-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05196867
The ClinicalTrials.gov registry entry for NCT05196867 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (80% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 2 interventions - of which Intervention Group is the first listed.
NCT05196867 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05196867 about?
NCT05196867 is a clinical study titled "Liver Cancer Prevention Randomized Control Trial". To determine the effectiveness of a behaviorally-based tailored disease management intervention in patients with fibrosis or steatosis and risk factors for cirrhosis.
What is the current status of trial NCT05196867?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 49 participants. The study started on 2022-02-11. Estimated completion is 2028-08-30.
What conditions does trial NCT05196867 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Liver Diseases, Fibrosis, Liver.
What interventions are being tested in trial NCT05196867?
The interventions under investigation include: Intervention Group (BEHAVIORAL), Control Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT05196867?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05196867 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis
RECRUITING · NA
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
RECRUITING · NA
-
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
RECRUITING · NA
-
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.